Here's our fresh take on the shares.
Patient investors could go long KN at current levels.
The shares have been cut in half over the last six months.
Here's how traders can play the stock.
Traders could go long ISRG at current levels.
Stand aside and let things "shake out".
Here's why the current weakness in Bionano Genomics could be a buying opportunity.
The news sent shares of the genome editing company skyward after the stock had been basing for months.
The 2021 Tax Loss Selling Recovery Portfolio didn't do much in April but is soundly beating the market six months after inception.
Let's look over the charts and indicators.